Hans Bishop
Chairman of Sana Biotechnology, Chief Executive Officer of GRAIL and President and founder at Altos Labs
Hans Bishop is the Chairman of Sana Biotechnology and the Chief Executive Officer of GRAIL.
Hans founded Juno Therapeutics in 2013 and served as its President and Chief Executive Officer until the company’s acquisition by Celgene. Prior to Juno, he served as an Executive in Residence at Warburg Pincus. Earlier in his career, Hans was the Executive Vice President and Chief Operating Officer for Dendreon. He also previously served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. In addition to serving as the Chair of Sana’s Board of Directors, he serves as a Director of Celgene, Agilent Technologies, and Lyell Immunopharma.
Hans holds a BA in chemistry from Brunel University in London.
Visit website: https://sana.com/team/hans-bishop/
See also: 
GRAIL
- GRAIL's mission is to detect cancer early, when it can be cured
Details last updated 23-Feb-2021
Hans Bishop News
Altos Labs comes out of stealth with $3 billion of capital
Genetic Engineering & Biotechnology News (GEN) - 19-Jan-2022
Huge backing that cellular reprogramming can have a significant impact on health and ageing
Read more...GRAIL partnered with the NHS to detect cancers early with a simple blood test
GRAIL - 11-Jan-2021
Hopefully this test could be available on the NHS later this year - form an orderly queue!
Read more...Illumina reunites with cancer testing firm Grail, worth $8 billion deal
FierceBiotech - 21-Sep-2020
Marks new era in advancing screening and early diagnosis of cancer technology
Read more...
